Fig. 1From: Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapyConsolidated Standards of Reporting Trials (CONSORT) diagram of patient disposition for patients randomized to receive dovitinib plus fulvestrant or placebo plus fulvestrant. FGF Fibroblast growth factorBack to article page